Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

Exclusion Criteria

• •Any clinically significant hematologic, endocrine, pulmonary, hepatic, gastrointestinal, or neurologic disease
• •Participant has any other concurrent pain condition that, in the opinion of the investigator, may significantly impact the current headache disorder
• •In the opinion of the investigator, confounding psychiatric conditions, dementia, epilepsy, or significant neurological disorders other than migraine
• •Has ≥ 15 headache days per month on average across the 3 months prior to Visit 1 in the investigator's judgment
• •Has ≥ 15 headache days in the 28-day baseline period per eDiary
• •Clinically significant cardiovascular or cerebrovascular disease
• •Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine as defined by ICHD-3, 2018
• •Has a current diagnosis of chronic migraine, new persistent daily headache, medication overuse headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3, 2018